|
Volumn 23, Issue 24, 2013, Pages 6585-6587
|
Discovery of an irreversible HCV NS5B polymerase inhibitor
a a a a a a a a a a a a a a a a a a a a more.. |
Author keywords
HCV; NS5B polymerase
|
Indexed keywords
ANTIVIRUS AGENT;
BOCEPREVIR;
NONSTRUCTURAL PROTEIN 5B;
NS5B POLYMERASE INHIBITOR;
RNA DIRECTED RNA POLYMERASE INHIBITOR;
TELAPREVIR;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
AREA UNDER THE CURVE;
ARTICLE;
CONFORMATIONAL TRANSITION;
COVALENT BOND;
DRUG BIOAVAILABILITY;
DRUG CLEARANCE;
DRUG DISTRIBUTION;
DRUG HALF LIFE;
DRUG METABOLISM;
DRUG POTENCY;
DRUG PROTEIN BINDING;
DRUG SAFETY;
DRUG SELECTIVITY;
DRUG SYNTHESIS;
ENZYME ASSAY;
ENZYME INACTIVATION;
ENZYME INHIBITION;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
IC 50;
MALE;
MAXIMUM PLASMA CONCENTRATION;
NONHUMAN;
RAT;
REACTION ANALYSIS;
STRUCTURE ACTIVITY RELATION;
HEPATITIS C VIRUS;
HCV;
NS5B POLYMERASE;
ANIMALS;
CRYSTALLOGRAPHY, X-RAY;
DOGS;
DRUG EVALUATION, PRECLINICAL;
ENZYME ACTIVATION;
ENZYME INHIBITORS;
HAPLORHINI;
HEPACIVIRUS;
HUMANS;
INDOLES;
MALE;
MOLECULAR DYNAMICS SIMULATION;
PROTEIN BINDING;
PROTEIN STRUCTURE, TERTIARY;
QUINOLINES;
RATS;
RATS, SPRAGUE-DAWLEY;
VIRAL NONSTRUCTURAL PROTEINS;
|
EID: 84888858768
PISSN: 0960894X
EISSN: 14643405
Source Type: Journal
DOI: 10.1016/j.bmcl.2013.10.060 Document Type: Article |
Times cited : (9)
|
References (15)
|